LILRB2 and non-small cell lung carcinoma: In fact, they demonstrated that ILT4 inhibition reversed the immunosuppressive features of the TME, so this approach might be a promising strategy for the second-line treatment in both TKI-resistant EGFR-mutated and EGFR wild-type NSCLC.